Exhibit 99.1











Picture 2



 

 

 

 

 



FOR IMMEDIATE RELEASE  

 

 



Alimera Sciences Announces Third Quarter 2020 Financial Results 

–  Rebound Continues from COVID Challenges



Third Quarter Highlights:

·

Consolidated Net Revenue of $12.5 Million Up 25% vs. Second Quarter 2020

·

U.S. Net Revenue of $7.0 Million Up 106% vs. Second Quarter 2020

·

Consolidated Net Revenue Down 3% vs. Third Quarter 2019

·

International Net Revenue Up 31% vs. Third Quarter 2019

·

Net Loss of ($0.6) Million vs. ($3.1) Million in Third Quarter 2019

·

Adjusted EBITDA of $1.4 Million vs. Negative $(0.5) Million Adjusted EBITDA in Third Quarter 2019



ATLANTA (October 28, 2020) – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the third quarter of 2020. Alimera will host a conference call on Thursday,  October 29, 2020 at 9:00 AM ET to review these financial results and provide an update on corporate developments.

Our strategy to retain our entire work force through the COVID-19 pandemic is paying off as we were able to drive a 25% sequential increase in global net revenue over the second quarter of 2020 and maintain sales through the first nine months of 2020 despite the challenges of the current environment,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “Importantly, we are achieving our goal of delivering positive adjusted EBITDA, reporting $1.4 million for the third quarter and $2.4 million year to date.

Mr. Eiswirth continued, During this challenging year we are continuing to invest in ILUVIEN® and to expand geographically to fuel our significant international growth. In the third quarter we initiated the NEW DAY study, our landmark clinical trial that we believe has the potential to position ILUVIEN as the preferred first-line treatment for diabetic macular edema, and we entered into partnerships to make ILUVIEN available in six additional countries in the future. 



 


 

Third Quarter 2020 Financial Results


Net Revenue

Consolidated net revenue for Q3 2020 was down 3% to $12.5 million, compared to $12.9 million for Q3 2019, and up 25% over Q2 2020.  



U.S. net revenue was $7.0 million for Q3 2020, down 20% from $8.7 million during the same period in 2019 but was 106%  over Q2 2020. End user demand, which represents units purchased by physicians and pharmacies from Alimera’s U.S. distributors, was 728 units in Q3 2020 compared to 973 units in Q3 2019, a decrease of 25%, but up sequentially from 625 units in Q2 2020 as some recovery from the COVID-19 impact was realized.



The difference between GAAP revenue and end user demand in the U.S. is due to the timing of distributor purchases from quarter to quarter. In both Q3 2020 and Q3 2019,  Alimera’s distributors purchased more units than they sold to end users, increasing their stock on hand during that quarter.  Distributors purchased approximately 19% and 9% more units than they sold to end users in Q3 2020 and Q3 2019, respectively.  



International net revenue increased 31% to approximately $5.5 million in Q3 2020, compared to approximately $4.2 million for the same period during 2019, primarily as a result of increased sales in the markets where we sell direct. These direct sales included sales revenue for our posterior uveitis indication.



Operating Expenses
Total operating expenses for Q3 2020 decreased by $2.5 million or 19% to $10.5 million, compared to $13.0 million during Q3 2019. Alimera achieved major expense reductions by reducing travel costs, decreasing attendance at medical conferences that were cancelled or converted to virtual meetings and reducing its spending on external commercial and medical affairs activities.  Additionally, Alimera benefitted from a one-time favorable impact of approximately $400,000 associated with recovery of previously paid VAT expense in Germany for the years 2014 through 2018.



Net Loss and Non-GAAP Adjusted EBITDA

For Q3 2020, Alimera reported a net loss of approximately $(0.6) million, compared to a net loss of $(3.1) million for Q3 2019. Adjusted EBITDA, a non-GAAP financial measure defined below, was approximately $1.4 million for Q3 2020, an improvement of approximately $1.9 million compared to negative Adjusted EBITDA of approximately $0.5 million for Q3 2019.



Net Loss per Share

Basic and diluted net loss per share for Q3 2020 was $(0.12). This compares to basic and diluted net loss per share for Q3 2019 of $(0.66). (The per share amounts in this press release reflect the impact from Alimera’s one-for-15 reverse stock split in November 2019.)



Cash and Cash Equivalents

As of September 30, 2020, Alimera had cash and cash equivalents of approximately $11.3 million, compared to $9.4 million as of December 31, 2019 and $13.5 million as of June 30,

 


 

2020. The sequential decrease in cash of $2.2 million from Q2 2020 reflects the impact of lower Q2 2020 revenue on working capital in 2020 and the planned one-time build-up of inventory for the transition of Alimera’s component manufacturing to the United States and related transition expenses.



Definition of Non-GAAP Financial Measure

For purposes of this press release, “Adjusted EBITDA” is defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains (losses) from foreign currency exchange transactions and severance expenses. Please refer to the sections of this press release entitled “Non-GAAP Financial Measure” and “Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA.”



Conference Call to Be Held October 29, 2020

Management will host a conference call at 9:00 AM ET on Thursday, October 29, 2020, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question and answer session.



Participants are asked to pre-register for the call.  Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast which is also available through the company’s website.



A  webcast replay of the call will be available approximately one hour after the end of the call through January 29, 2021. The replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10149051. The telephonic replay will be available until November 12, 2020.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally. For more information, please visit www.alimerasciences.com.

Non-GAAP Financial Measure

This press release contains a discussion of Adjusted EBITDA,  a non-GAAP financial measure, as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. Alimera reports its financial results in compliance with GAAP but believes that the non-GAAP measure of Adjusted EBITDA provides useful information to investors regarding Alimera’s

 


 

operating performance.  Alimera uses Adjusted EBITDA in the management of its business. Accordingly, Adjusted EBITDA for the three and nine months ended September 30, 2020 and 2019 has been presented in certain instances excluding items identified in the reconciliations provided in the table entitled “Reconciliation of GAAP Net Loss to non-GAAP Adjusted EBITDA.” GAAP net loss is the most directly comparable GAAP financial measure to Adjusted EBITDA. 

Adjusted EBITDA, as presented, may not be comparable to similarly titled measures reported by other companies because not all companies calculate Adjusted EBITDA in an identical manner. Therefore, Adjusted EBITDA is not necessarily an accurate measure of comparison between companies.

The presentation of Adjusted EBITDA is not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management in determining this non-GAAP financial measure.

About ILUVIEN

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING technology, ILUVIEN is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease. ILUVIEN enables patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Australia, Canada, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN is indicated in 17 European countries for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies and in 16 European countries for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Alimera does not have the contractual right to pursue approval to treat uveitis in the U.S., and therefore does not have a regulatory license in the U.S. to treat NIPU. For important safety information on ILUVIEN, see https://iluvien.com/#isi

Forward Looking Statements

This press release contains, and the remarks by Alimera’s officers on the conference call may contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations with respect to its strategy to retain its work force through the COVID-19 pandemic to continue to drive revenue, its ability to continue to deliver positive adjusted EBITDA, its ability to continue investing in ILUVIEN and expanding geographically, its ability to position ILUVIEN as the preferred first-line treatment for DME through the NEW DAY Study and the ability of new partners to make ILUVIEN available in additional countries. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could

 


 

delay, divert or change them, and could cause actual results to differ materially from those projected in the forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to, continuing risks relating to the COVID-19 pandemic that could (a) reverse the current trends in Alimera’s revenues and Adjusted EBITDA,  due to increased COVID-19 cases in certain states within the U.S. and in Alimera’s international markets that have resulted or may again result in reduced access to medical facilities for patient visits with their physicians and continuing concerns of patients with diabetes who may be unwilling to visit their physicians in person (even if otherwise permitted) due to their fear of contracting COVID-19,  (b) adversely affect Alimera’s ability to maintain its work force and (c) limit Alimera’s ability to continue investing in ILUVIEN and expanding geographically. Other meaningful factors that could cause actual results to differ include (i) risks associated with conducting the NEW DAY study during a pandemic and other risks of such a study, including the risk that the results may not meet Alimera’s expectations that it will position ILUVIEN as the preferred first-line treatment for DME, and (ii) regulatory and business risks in the countries in which Alimera’s new partners are or will be seeking proper authorization for the sale of ILUVIEN. Other factors are discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2019 and Alimera’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, which are on file with the Securities and Exchange Commission (SEC) and are available on the SEC’s website at http://www.sec.gov. Applicable risk factors will also be described in those sections of Alimera’s Quarterly Report on Form 10-Q for the third quarter of 2020, to be filed with the SEC soon.



The forward-looking statements in this press release speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether due to new information, future events or otherwise.



For investor inquiries:                                                  For media inquiries:

Scott Gordon                                                                   Jules Abraham

for Alimera Sciences                                                      for Alimera Sciences
scottg@coreir.com                                                         julesa@coreir.com


   #  #

     

























 


 

ALIMERA SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)



 

 

 

 

 



 

 

 

 

 



September 30,

 

December 31,



2020

 

2019



(unaudited)

 

 

CURRENT ASSETS:

 

 

 

 

 

Cash and cash equivalents

$

11,254 

 

$

9,426 

Restricted cash

 

32 

 

 

33 

Accounts receivable, net

 

15,628 

 

 

19,331 

Prepaid expenses and other current assets

 

3,177 

 

 

2,565 

Inventory

 

2,522 

 

 

1,390 

Total current assets

 

32,613 

 

 

32,745 

NON-CURRENT ASSETS:

 

 

 

 

 

Property and equipment, net

 

1,582 

 

 

940 

Right of use assets, net

 

791 

 

 

1,107 

Intangible asset, net

 

13,327 

 

 

14,783 

Deferred tax asset

 

767 

 

 

734 

TOTAL ASSETS

$

49,080 

 

$

50,309 

CURRENT LIABILITIES:

 

 

 

 

 

Accounts payable

$

5,356 

 

$

7,077 

Accrued expenses

 

3,475 

 

 

4,716 

Notes payable

 

1,185 

 

 

 —

Finance lease obligations

 

219 

 

 

255 

Total current liabilities

 

10,235 

 

 

12,048 

NON-CURRENT LIABILITIES:

 

 

 

 

 

Note payable, net of discount

 

42,459 

 

 

38,658 

Finance lease obligations — less current portion

 

452 

 

 

94 

Other non-current liabilities

 

3,567 

 

 

3,954 

COMMITMENTS AND CONTINGENCIES

 

 

 

 

 

STOCKHOLDERS’ DEFICIT:

 

 

 

 

 

Preferred stock:

 

 

 

 

 

Series A Convertible Preferred Stock

 

19,227 

 

 

19,227 

Series C Convertible Preferred Stock

 

9,474 

 

 

11,117 

Common stock

 

51 

 

 

50 

Additional paid-in capital

 

352,728 

 

 

350,117 

Common stock warrants

 

3,707 

 

 

3,707 

Accumulated deficit

 

(391,932)

 

 

(387,570)

Accumulated other comprehensive loss

 

(888)

 

 

(1,093)

TOTAL STOCKHOLDERS’ DEFICIT

 

(7,633)

 

 

(4,445)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

$

49,080 

 

$

50,309 

 


 

ALIMERA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019

(in thousands, except share and per share data)





 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



Three Months Ended

 

Nine Months Ended



September 30,

 

September 30,



2020

 

2019

 

2020

 

2019



(unaudited)

NET REVENUE

$

12,473 

 

$

12,850 

 

$

37,046 

 

$

36,595 

COST OF GOODS SOLD, EXCLUDING

DEPRECIATION AND AMORTIZATION

 

(1,537)

 

 

(1,579)

 

 

(4,949)

 

 

(4,353)

GROSS PROFIT

 

10,936 

 

 

11,271 

 

 

32,097 

 

 

32,242 

RESEARCH, DEVELOPMENT AND

MEDICAL AFFAIRS EXPENSES

 

2,469 

 

 

2,761 

 

 

7,162 

 

 

8,322 

GENERAL AND ADMINISTRATIVE EXPENSES

 

2,619 

 

 

3,121 

 

 

8,775 

 

 

10,189 

SALES AND MARKETING EXPENSES

 

4,764 

 

 

6,437 

 

 

14,818 

 

 

18,458 

DEPRECIATION AND AMORTIZATION

 

677 

 

 

668 

 

 

2,016 

 

 

1,974 

OPERATING EXPENSES

 

10,529 

 

 

12,987 

 

 

32,771 

 

 

38,943 

NET INCOME (LOSS) FROM OPERATIONS

 

407 

 

 

(1,716)

 

 

(674)

 

 

(6,701)

INTEREST EXPENSE AND OTHER

 

(1,285)

 

 

(1,232)

 

 

(3,928)

 

 

(3,696)

UNREALIZED FOREIGN CURRENCY

GAIN (LOSS), NET

 

267 

 

 

(115)

 

 

295 

 

 

(135)

NET LOSS BEFORE TAXES

 

(611)

 

 

(3,063)

 

 

(4,307)

 

 

(10,532)

PROVISION FOR TAXES

 

(7)

 

 

(77)

 

 

(55)

 

 

(409)

NET LOSS

$

(618)

 

$

(3,140)

 

$

(4,362)

 

$

(10,941)

NET LOSS PER COMMON SHARE — Basic and diluted

$

(0.12)

 

$

(0.66)

 

$

(0.87)

 

$

(2.31)

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING — Basic and diluted

 

5,068,701 

 

 

4,733,484 

 

 

5,026,905 

 

 

4,727,472 



 


 

ALIMERA SCIENCES, INC.

CONSOLIDATING STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019

(in thousands)





 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Three Months Ended

 

Three Months Ended



September 30, 2020

 

September 30, 2019



U.S.

 

International

 

Other

 

Consolidated

 

U.S.

 

International

 

Other

 

Consolidated



(unaudited)

NET REVENUE

$

6,962 

 

$

5,511 

 

$

 —

 

$

12,473 

 

$

8,692 

 

$

4,158 

 

$

 —

 

$

12,850 

COST OF GOODS SOLD, EXCLUDING

DEPRECIATION AND

AMORTIZATION

 

(746)

 

 

(791)

 

 

 

 

(1,537)

 

 

(1,001)

 

 

(578)

 

 

 —

 

 

(1,579)

GROSS PROFIT

 

6,216 

 

 

4,720 

 

 

 

 

10,936 

 

 

7,691 

 

 

3,580 

 

 

 —

 

 

11,271 

RESEARCH, DEVELOPMENT AND

MEDICAL AFFAIRS EXPENSES

 

1,560 

 

 

861 

 

 

48 

 

 

2,469 

 

 

1,573 

 

 

1,100 

 

 

88 

 

 

2,761 

GENERAL AND ADMINISTRATIVE

EXPENSES

 

1,952 

 

 

475 

 

 

192 

 

 

2,619 

 

 

2,032 

 

 

768 

 

 

321 

 

 

3,121 

SALES AND MARKETING EXPENSES

 

3,461 

 

 

1,226 

 

 

77 

 

 

4,764 

 

 

4,502 

 

 

1,840 

 

 

95 

 

 

6,437 

DEPRECIATION AND

AMORTIZATION

 

 

 

 

 

677 

 

 

677 

 

 

 —

 

 

 —

 

 

668 

 

 

668 

OPERATING EXPENSES

 

6,973 

 

 

2,562 

 

 

994 

 

 

10,529 

 

 

8,107 

 

 

3,708 

 

 

1,172 

 

 

12,987 

SEGMENT (LOSS) INCOME FROM

OPERATIONS

 

(757)

 

 

2,158 

 

 

(994)

 

 

407 

 

 

(416)

 

 

(128)

 

 

(1,172)

 

 

(1,716)

OTHER INCOME AND EXPENSES,

NET

 

 

 

 

 

(1,018)

 

 

(1,018)

 

 

 —

 

 

 —

 

 

(1,347)

 

 

(1,347)

NET LOSS BEFORE TAXES

 

 

 

 

 

 

 

 

 

$

(611)

 

 

 

 

 

 

 

 

 

 

$

(3,063)



 


 

ALIMERA SCIENCES, INC.

CONSOLIDATING STATEMENTS OF OPERATIONS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019

(in thousands)



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Nine Months Ended

 

Nine Months Ended



September 30, 2020

 

September 30, 2019



U.S.

 

International

 

Other

 

Consolidated

 

U.S.

 

International

 

Other

 

Consolidated



(unaudited)

NET REVENUE

$

17,449 

 

$

19,597 

 

$

 —

 

$

37,046 

 

$

22,778 

 

$

13,817 

 

$

 —

 

$

36,595 

COST OF GOODS SOLD, EXCLUDING

DEPRECIATION AND

AMORTIZATION

 

(1,928)

 

 

(3,021)

 

 

 —

 

 

(4,949)

 

 

(2,494)

 

 

(1,859)

 

 

 —

 

 

(4,353)

GROSS PROFIT

 

15,521 

 

 

16,576 

 

 

 —

 

 

32,097 

 

 

20,284 

 

 

11,958 

 

 

 —

 

 

32,242 

RESEARCH, DEVELOPMENT AND

MEDICAL AFFAIRS EXPENSES

 

4,580 

 

 

2,418 

 

 

164 

 

 

7,162 

 

 

4,629 

 

 

3,361 

 

 

332 

 

 

8,322 

GENERAL AND ADMINISTRATIVE

EXPENSES

 

5,867 

 

 

2,250 

 

 

658 

 

 

8,775 

 

 

6,116 

 

 

2,876 

 

 

1,197 

 

 

10,189 

SALES AND MARKETING EXPENSES

 

10,948 

 

 

3,618 

 

 

252 

 

 

14,818 

 

 

12,760 

 

 

5,324 

 

 

374 

 

 

18,458 

DEPRECIATION AND

AMORTIZATION

 

 —

 

 

 —

 

 

2,016 

 

 

2,016 

 

 

 —

 

 

 —

 

 

1,974 

 

 

1,974 

OPERATING EXPENSES

 

21,395 

 

 

8,286 

 

 

3,090 

 

 

32,771 

 

 

23,505 

 

 

11,561 

 

 

3,877 

 

 

38,943 

SEGMENT (LOSS) INCOME FROM

OPERATIONS

 

(5,874)

 

 

8,290 

 

 

(3,090)

 

 

(674)

 

 

(3,221)

 

 

397 

 

 

(3,877)

 

 

(6,701)

OTHER INCOME AND EXPENSES,

NET

 

 —

 

 

 —

 

 

(3,633)

 

 

(3,633)

 

 

 —

 

 

 —

 

 

(3,831)

 

 

(3,831)

NET LOSS BEFORE TAXES

 

 

 

 

 

 

 

 

 

$

(4,307)

 

 

 

 

 

 

 

 

 

 

$

(10,532)



 


 

RECONCILIATION OF GAAP MEASURES TO NON-GAAP ADJUSTED MEASURES

GAAP NET INCOME OR LOSS TO NON-GAAP ADJUSTED EBITDA

(in thousands)



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

2020

 

2019

 

2020

 

2019

 

(unaudited)

GAAP NET LOSS

$

(618)

 

 

 

$

(3,140)

 

 

 

$

(4,362)

 

 

 

$

(10,941)

 

 

Adjustments to net loss:

 

 

 

 

 

 

 

Interest expense and other

1,285 

 

 

1,232 

 

 

3,928 

 

 

3,696 

 

Provision for taxes

 

 

77 

 

 

55 

 

 

409 

 

Depreciation and amortization

677 

 

 

668 

 

 

2,016 

 

 

1,974 

 

Stock-based compensation expenses

317 

 

 

504 

 

 

1,074 

 

 

1,903 

 

Unrealized foreign currency exchange (gains) losses

(267)

 

 

115 

 

 

(295)

 

 

135 

 

Severance expenses

 

 

23 

 

 

 

 

198 

 

NON-GAAP ADJUSTED EBITDA

$

1,401 

 

 

 

$

(521)

 

 

 

$

2,416 

 

 

 

$

(2,626)

 

 







 


View differences made from one to another to evaluate Alimera Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alimera Sciences Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account